Overexpression of pre-pro-cholecystokinin stimulates β-cell proliferation in mouse and human islets with retention of islet function

Jeremy A. Lavine, Phil Raess, Dawn Belt Davis, Mary E. Rabaglia, Brent K. Presley, Mark P. Keller, Margery C. Beinfeld, Alan S. Kopin, Christopher B. Newgard, Alan D. Attie

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Type 1 and type 2 diabetes result from a deficit in insulin production and β-cell mass. Methods to expand β-cell mass are under intensive investigation for the treatment of type 1 and type 2 diabetes. We tested the hypothesis that cholecystokinin (CCK) can promote β-cell proliferation. We treated isolated mouse and human islets with an adenovirus containing the CCK cDNA (AdCMV-CCK). We measured [3H]thymidine and BrdU incorporation into DNA and additionally, performed flow cytometry analysis to determine whether CCK overexpression stimulates β-cell proliferation. We studied islet function by measuring glucose-stimulated insulin secretion and investigated the cell cycle regulation of proliferating β-cells by quantitative RTPCR and Western blot analysis. Overexpression of CCK stimulated [3H]thymidine incorporation into DNA 5.0-fold and 15.8-fold in mouse and human islets, respectively. AdCMV-CCK treatment also stimulated BrdU incorporation into DNA 10-fold and 21-fold in mouse and human β-cells, respectively. Glucose-stimulated insulin secretion was unaffected by CCK expression. Analysis of cyclin and cdk mRNA and protein abundance revealed that CCK overexpression increased cyclin A, cyclin B, cyclin E, cdk1, and cdk2 with no change in cyclin D1, cyclin D2, cyclin D3, cdk4, or cdk6 in mouse and human islets. Additionally, AdCMV-CCK treatment of CCK receptor knockout and wild-type mice resulted in equal [3H]thymidine incorporation. CCK is a β-cell proliferative factor that is effective in both mouse and human islets. CCK triggers β-cell proliferation without disrupting islet function, up-regulates a distinct set of cell cycle regulators in islets, and signals independently of the CCK receptors.

Original languageEnglish (US)
Pages (from-to)2716-2728
Number of pages13
JournalMolecular Endocrinology
Volume22
Issue number12
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Cholecystokinin
Cell Proliferation
Thymidine
Cholecystokinin Receptors
Bromodeoxyuridine
Insulin
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
DNA
Cell Cycle
Cyclin D3
Cyclin D2
Cyclin B
Glucose
Cyclin A
Cyclin E
Cyclins
Cyclin-Dependent Kinases
Cyclin D1
Adenoviridae

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Overexpression of pre-pro-cholecystokinin stimulates β-cell proliferation in mouse and human islets with retention of islet function. / Lavine, Jeremy A.; Raess, Phil; Davis, Dawn Belt; Rabaglia, Mary E.; Presley, Brent K.; Keller, Mark P.; Beinfeld, Margery C.; Kopin, Alan S.; Newgard, Christopher B.; Attie, Alan D.

In: Molecular Endocrinology, Vol. 22, No. 12, 01.12.2008, p. 2716-2728.

Research output: Contribution to journalArticle

Lavine, JA, Raess, P, Davis, DB, Rabaglia, ME, Presley, BK, Keller, MP, Beinfeld, MC, Kopin, AS, Newgard, CB & Attie, AD 2008, 'Overexpression of pre-pro-cholecystokinin stimulates β-cell proliferation in mouse and human islets with retention of islet function', Molecular Endocrinology, vol. 22, no. 12, pp. 2716-2728. https://doi.org/10.1210/me.2008-0255
Lavine, Jeremy A. ; Raess, Phil ; Davis, Dawn Belt ; Rabaglia, Mary E. ; Presley, Brent K. ; Keller, Mark P. ; Beinfeld, Margery C. ; Kopin, Alan S. ; Newgard, Christopher B. ; Attie, Alan D. / Overexpression of pre-pro-cholecystokinin stimulates β-cell proliferation in mouse and human islets with retention of islet function. In: Molecular Endocrinology. 2008 ; Vol. 22, No. 12. pp. 2716-2728.
@article{58860e14c49b4e4ca3bfebede0ea90a2,
title = "Overexpression of pre-pro-cholecystokinin stimulates β-cell proliferation in mouse and human islets with retention of islet function",
abstract = "Type 1 and type 2 diabetes result from a deficit in insulin production and β-cell mass. Methods to expand β-cell mass are under intensive investigation for the treatment of type 1 and type 2 diabetes. We tested the hypothesis that cholecystokinin (CCK) can promote β-cell proliferation. We treated isolated mouse and human islets with an adenovirus containing the CCK cDNA (AdCMV-CCK). We measured [3H]thymidine and BrdU incorporation into DNA and additionally, performed flow cytometry analysis to determine whether CCK overexpression stimulates β-cell proliferation. We studied islet function by measuring glucose-stimulated insulin secretion and investigated the cell cycle regulation of proliferating β-cells by quantitative RTPCR and Western blot analysis. Overexpression of CCK stimulated [3H]thymidine incorporation into DNA 5.0-fold and 15.8-fold in mouse and human islets, respectively. AdCMV-CCK treatment also stimulated BrdU incorporation into DNA 10-fold and 21-fold in mouse and human β-cells, respectively. Glucose-stimulated insulin secretion was unaffected by CCK expression. Analysis of cyclin and cdk mRNA and protein abundance revealed that CCK overexpression increased cyclin A, cyclin B, cyclin E, cdk1, and cdk2 with no change in cyclin D1, cyclin D2, cyclin D3, cdk4, or cdk6 in mouse and human islets. Additionally, AdCMV-CCK treatment of CCK receptor knockout and wild-type mice resulted in equal [3H]thymidine incorporation. CCK is a β-cell proliferative factor that is effective in both mouse and human islets. CCK triggers β-cell proliferation without disrupting islet function, up-regulates a distinct set of cell cycle regulators in islets, and signals independently of the CCK receptors.",
author = "Lavine, {Jeremy A.} and Phil Raess and Davis, {Dawn Belt} and Rabaglia, {Mary E.} and Presley, {Brent K.} and Keller, {Mark P.} and Beinfeld, {Margery C.} and Kopin, {Alan S.} and Newgard, {Christopher B.} and Attie, {Alan D.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1210/me.2008-0255",
language = "English (US)",
volume = "22",
pages = "2716--2728",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Overexpression of pre-pro-cholecystokinin stimulates β-cell proliferation in mouse and human islets with retention of islet function

AU - Lavine, Jeremy A.

AU - Raess, Phil

AU - Davis, Dawn Belt

AU - Rabaglia, Mary E.

AU - Presley, Brent K.

AU - Keller, Mark P.

AU - Beinfeld, Margery C.

AU - Kopin, Alan S.

AU - Newgard, Christopher B.

AU - Attie, Alan D.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Type 1 and type 2 diabetes result from a deficit in insulin production and β-cell mass. Methods to expand β-cell mass are under intensive investigation for the treatment of type 1 and type 2 diabetes. We tested the hypothesis that cholecystokinin (CCK) can promote β-cell proliferation. We treated isolated mouse and human islets with an adenovirus containing the CCK cDNA (AdCMV-CCK). We measured [3H]thymidine and BrdU incorporation into DNA and additionally, performed flow cytometry analysis to determine whether CCK overexpression stimulates β-cell proliferation. We studied islet function by measuring glucose-stimulated insulin secretion and investigated the cell cycle regulation of proliferating β-cells by quantitative RTPCR and Western blot analysis. Overexpression of CCK stimulated [3H]thymidine incorporation into DNA 5.0-fold and 15.8-fold in mouse and human islets, respectively. AdCMV-CCK treatment also stimulated BrdU incorporation into DNA 10-fold and 21-fold in mouse and human β-cells, respectively. Glucose-stimulated insulin secretion was unaffected by CCK expression. Analysis of cyclin and cdk mRNA and protein abundance revealed that CCK overexpression increased cyclin A, cyclin B, cyclin E, cdk1, and cdk2 with no change in cyclin D1, cyclin D2, cyclin D3, cdk4, or cdk6 in mouse and human islets. Additionally, AdCMV-CCK treatment of CCK receptor knockout and wild-type mice resulted in equal [3H]thymidine incorporation. CCK is a β-cell proliferative factor that is effective in both mouse and human islets. CCK triggers β-cell proliferation without disrupting islet function, up-regulates a distinct set of cell cycle regulators in islets, and signals independently of the CCK receptors.

AB - Type 1 and type 2 diabetes result from a deficit in insulin production and β-cell mass. Methods to expand β-cell mass are under intensive investigation for the treatment of type 1 and type 2 diabetes. We tested the hypothesis that cholecystokinin (CCK) can promote β-cell proliferation. We treated isolated mouse and human islets with an adenovirus containing the CCK cDNA (AdCMV-CCK). We measured [3H]thymidine and BrdU incorporation into DNA and additionally, performed flow cytometry analysis to determine whether CCK overexpression stimulates β-cell proliferation. We studied islet function by measuring glucose-stimulated insulin secretion and investigated the cell cycle regulation of proliferating β-cells by quantitative RTPCR and Western blot analysis. Overexpression of CCK stimulated [3H]thymidine incorporation into DNA 5.0-fold and 15.8-fold in mouse and human islets, respectively. AdCMV-CCK treatment also stimulated BrdU incorporation into DNA 10-fold and 21-fold in mouse and human β-cells, respectively. Glucose-stimulated insulin secretion was unaffected by CCK expression. Analysis of cyclin and cdk mRNA and protein abundance revealed that CCK overexpression increased cyclin A, cyclin B, cyclin E, cdk1, and cdk2 with no change in cyclin D1, cyclin D2, cyclin D3, cdk4, or cdk6 in mouse and human islets. Additionally, AdCMV-CCK treatment of CCK receptor knockout and wild-type mice resulted in equal [3H]thymidine incorporation. CCK is a β-cell proliferative factor that is effective in both mouse and human islets. CCK triggers β-cell proliferation without disrupting islet function, up-regulates a distinct set of cell cycle regulators in islets, and signals independently of the CCK receptors.

UR - http://www.scopus.com/inward/record.url?scp=56749105741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749105741&partnerID=8YFLogxK

U2 - 10.1210/me.2008-0255

DO - 10.1210/me.2008-0255

M3 - Article

C2 - 18845673

AN - SCOPUS:56749105741

VL - 22

SP - 2716

EP - 2728

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 12

ER -